A B S T R AC T
Background. To determine the incidence and significance of acute kidney injury (AKI) after initiating highly active antiretroviral therapy (HAART). Methods. A prospective cohort study of 271 consecutively treated HIV-infected patients, initiating first (75) or sequential HAART (196) from January 2008 to June 2011. AKI was diagnosed according to the Risk, Injury, Failure, Loss of kidney function, End-stage renal disease (RIFLE)/Acute Kidney Injury Network (AKIN) criteria, and the risk of progression to chronic kidney disease (CKD) was evaluated. Results. A greater estimated glomerular filtration rate (eGFR) decrease after 1 year was observed for patients initiating a tenofovir disoproxil fumarate (TDF)-based regimen (−6.45 versus +0.98 mL/min/1.73 m 2 when compared with patients without TDF; P < 0.01), both in the case of the first (−8.5 versus −2.27; P = 0.04) or successive regimens (−5.3 versus + 1.18 mL/min/1.73 m 2 ; P < 0.01). AKI, as defined, was observed in 10% (28 cases, 6 .98 episodes/100 patients-year), mostly stage I (27 cases), in a median time of 6 (3-16.5) months. Four cases (14%), having a worse baseline renal function progressed to CKD, whereas four recovered completely. In the multivariate analysis, AKI was associated with the concomitant use of cotrimoxazole prophylaxis and to low CD4+ count. CKD was diagnosed in 2% (six cases) of patients. Therefore, the overall rate of HAART-associated renal disorders was 11% (30 cases, 7.46 episodes/100 patients-year (95% confidence interval, 6.09-8.83). Conclusions. The initiation of a tenofovir-based regimen is followed by a significant decline in eGFR, although it could be misinterpreted by the concomitant use of cotrimoxazole. A substantial proportion of patients develop AKI, but only a minority progress to CKD. Patients initiating HAART and developing AKI should be carefully monitored for progression of renal disease.
I N T R O D U C T I O N
The introduction of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection has led to a dramatic decline in mortality and morbidity [1] . As patients survive longer, renal disease has become an important contributing factor to morbidity and mortality [2] .
While HAART has been demonstrated to reduce the incidence and severity of HIV-associated nephropathy (HIVAN) [3] , antiretroviral drugs have been associated with alteration of renal function, as shown by a decrease in the glomerular filtration rate (GFR). Specifically, tenofovir disoproxil fumarate (TDF) is a reverse transcriptase inhibitor nucleotide excreted by the kidney through a combination of glomerular filtration and active tubular secretion [4] . During previous years, there have been a lot of studies describing the incidence and prevalence of renal toxicity associated with the use of TDF [5] [6] [7] . However, most of the studies used different definitions for toxicity [including acute drop in GFR, ranging from 10 to 50%, or the development of chronic kidney disease (CKD)], in different populations (naives or pretreated, clinical trials or observational studies). A recent meta-analysis that included data from 17 studies concluded that patients treated with TDF experienced a significant but small loss of kidney function during the course of treatment compared with controls [estimated GFR (eGFR) mean difference, −3.9 mL/min] [8], a figure not reaching established criteria of acute kidney injury (AKI) or CKD [9] .
Furthermore, one of the most controversial issues is the significance of AKI in this population. The concept of AKI was derived from acute renal failure, and includes patients with a sudden increase in serum creatinine (SCr) or a decrease in GFR, establishing patients with the risk of progression after injury. AKI is associated with significant mortality, hospital length of stay and economic costs, particularly in the context of critically ill patients in the intensive care setting [10, 11] . HIV-infected patients appear to have higher risk for AKI compared with HIV-uninfected persons [12] . Among hospitalized HIV-infected patients, those with AKI were 1.37 times more likely to progress to CKD compared with those who did not develop AKI [13] . It should be noted, however, that only a small proportion of AKI patients (<5%) sustain severe AKI or require dialysis, whereas the majority of AKI patients experienced milder degrees of kidney injury [14] , and even this definition could be less predictive in asymptomatic, ambulatory patients.
Thus, the clinical significance of an initial decline in renal function, which occurs often in HIV-infected individuals, remains unclear. We investigated the clinical impact of a welldefined and easily applicable definition of AKI in a closely monitored cohort of HIV-infected patients initiating HAART, according to the presence of other risk factors.
M AT E R I A L S A N D M E T H O D S
This is a prospective observational cohort study of naïve and treatment-experienced HIV-positive patients who initiate a new antiretroviral regimen in the period between 1 January 2008 and 1 June 2011. The study was conducted within the guidelines of ethical principles, local legislation and the local institutional review board. All patients visiting our unit who received HAART during the study period were eligible for inclusion if they were older than 18 years and had a baseline (<1 month before inclusion) eGFR of >60 mL/min. Patients with end-stage renal disease (ESRD), including those on dialysis programmes, any opportunistic infection for 1 month around inclusion, liver cirrhosis Child-Pugh stage B or C, previous therapy including TDF or without at least two determinations of renal function during the follow-up were excluded. Of note, patients with a history of prior renal disease (nephrolitiasis, HIVAN and renal toxicity) were included if they met the criteria for inclusion.
Data collection
Patients were managed according to clinical guidelines with a follow-up visit every 3 months with renal function assessment. The following clinical information and laboratory data were collected for each patient included: sex, race, baseline plus at least two additional SCr values. An eGFR (standardized for body surface area), using the four-variable Modification of Diet in Renal Disease equation (MDRD) was calculated for each time point at which an SCr value was available [15] , and retrospectively corroborated by using the Chronic Kidney Disease Epidemiological Collaboration (CKD-epi) formula, since the MDRD equation may overestimate the severity of renal impairment in HIV-infected patients [16] . A complete antiretroviral and other potentially nephrotoxic medication treatment history was also collected [nephrotoxic medications recorded included non-steroidal anti-inflammatory drugs (NSAID), angiotensin-converting enzyme inhibitors (ACE-I), angiotensin-II receptor blockers (ARB), amphotericin B, foscarnet, colistin, tacrolimus, cotrimoxazole and cyclosporine], and so were the CD4 count and the HIV-1 RNA level during the follow-up and diagnosis of selected co-morbidities including hypertension and diabetes mellitus, and chronic co-infection with hepatitis B or C virus. The CD4+ cell count was measured by flow cytometry and the HIV RNA level by bDNA (Bayer diagnostics) with a lower limit of quantification of 50 copies/mL.
Outcome measures
The primary end point was the incidence of AKI, defined according to the Risk, Injury, Failure, Loss of kidney function, End-stage renal disease (RIFLE) classification in 2004, and modified by the Acute Kidney Injury Network (AKIN) classification in 2007 [17, 18] , as a 25% or greater acute decline in eGFR from baseline on one or more measurements, or an SCr >1.5 mg/dL (>132 mmol/L), or a 0.3 mg/dL (26.4 mmol/L) increase in SCr above baseline. This definition includes recategorization of the original RIFLE into AKIN stages 1, 2 and 3, by the addition of an absolute increase in creatinine to stage 1 criteria. Since patients were ambulatory, urine output criterion was not considered for diagnosis. Also, since the AKI definition includes a period of 48 h and patients were managed according to clinical visits, the presence of infection, sepsis, postrenal disease (stones, crystalluria) or causes of volume depletion were ruled out. The diagnosis of CKD was defined as an eGFR of <60 mL/min/1.73 m 2 on two consecutive measurements separated by 3 months, which constitutes stage 3 or greater CKD [9] .
The incidence of AKI was calculated globally and in different subgroups to characterize risk factors. Patients with AKI were followed to determine the risk of progression to CKD, treatment discontinuation and death. The end of follow-up was the date of discontinuation, death or of the last available SCr-eGFR value until June 2011. Patients who changed TDF during the follow-up without AKI criteria were included until discontinuation. Any patient who received TDF prior to the study end, regardless of if treatment experienced or not, was characterized as TDF exposed. Patients were characterized as TDF unexposed if they did not receive TDF during the study period.
Statistical analysis
All patients who visited during the study period at our unit were screened for inclusion, comprising a sample size of convenience. Statistical analyses were performed to assess the potential differences between patients who developed AKI versus patients who did not, as well as to detect the baseline differences between patients exposed versus not exposed to TDF, and between prior naive and treatment-experienced patients. AKI incidence rates (IRs) were calculated by dividing the number of events by person time at risk. IRs were calculated for first AKI events, but not for subsequent events. We used the chi-square test to assess the associations between AKI and TDF exposure, and associations between categorical independent variables and AKI. Associations between continuous variables were evaluated using Student's t-test or the Mann-Whitney U-test if the variable followed a normal distribution or not. Significant variables in the univariate analysis were included in a logistic multivariate regression model for a multivariate analysis. All statistical analyses were performed with SPSS version 9.0 (SPSS, Inc., Chicago, IL).
R E S U LT S
Six hundred and seventy-nine (679) patients initiated a new antiretroviral regimen during the study period. Three hundred and fifty-six (356) had received or were receiving TDF at baseline, 2 were on a dialysis programme, 12 had advanced liver cirrhosis, 27 patients interrupted therapy before renal evaluation (not related to renal events) and 11 patients were excluded because of insufficient follow-up (lack of at least two determinations of renal function after therapy initiation). Thus, 271 patients were included in the final analysis, representing a follow-up of 401 patient-years on antiretroviral treatment. Overall, 75 patients (27.7%) were receiving their first antiretroviral regimen (66 with TDF), and 196 (72.3%) were treatment-experienced patients who changed their antiretroviral regimen (114 initiating TDF). Baseline characteristics of TDF exposed and unexposed, and of naive or treatmentexperienced patients, are shown in Table 1 . As expected, significant differences were found between naive and treatmentexperienced patients in the risk factors for HIV infection, race, antiretroviral regimen prescribed, prevalence of hepatitis C virus (HCV) coinfection and the lowest CD4 count (nadir), differences that represent the epidemiological changes observed in the characteristics of patients with HIV infection in past years. Previous time on antiretroviral therapy was shorter in experienced patients initiating TDF (10.9 ± 6.2 versus 14.2 ± 5.8, P < 0.01). Of note, there were no differences in renal function assessed either by SCr or eGFR at baseline (MDRD and CKD-epi equations). Also, characteristics were similar according to TDF exposure, with significant differences in the percentage of male patients and in the baseline CD4 count and baseline viral load.
During a mean follow-up of 1.48 ± 0.6 years, eGFR changed by a mean of −3.9 mL/min/1.73 m 2 (±19.06). AKI, as defined, was observed in 28 patients [10%, IR 6.98 episodes/ 100 patient-years; 95% confidence interval (CI) 5.5-8.42]. Of them, 27 had an eGFR decrease >25% (risk according to the RIFLE classification, AKIN stage I) and only 1 patient had a decrease >50% (injury, AKIN stage II). These cases appeared mainly in the first months of treatment with a median of 6 (3-16.5) months. In a univariate analysis of risk factors (Table 2) , AKI was associated with the use of the combination of TDF plus protease inhibitor (64 versus 36%; P = 0.002), use of cotrimoxazole as prophylaxis (36 versus 9%; P < 0.001), a lower baseline SCr (0.8 ± 0.2 versus 0.9 ± 0.1 mg/dl; P = 0.02), a higher baseline eGFR (116.3 ± 32.3 versus 103 ± 20.7 mL/min/ 1.73 m 2 ; P = 0.04), a lower baseline CD4 count (178 versus 394 cells/μL; P < 0.001) and a higher baseline viral load (3.74 versus 1.7 log copies/mL; P = 0.006). Specifically, the concomitant use of cotrimoxazole was observed in 32 patients (12%, 25 with TDF), resulting in a greater eGFR decrease after 1 year, both in the case of TDF-treated patients (−15.7 versus −4.8 mL/min/1.73 m 2 ; P = 0.03) and for patients without TDF (−7.12 versus +1.6 mL/min/1.73 m 2 ; P = 0.1). The differences between TDF and without TDF continue to be statistically significant in patients not receiving cotrimoxazole (P < 0.01). In a logistic regression analysis with AKI as a dependent variable, only the concomitant use of cotrimoxazole (RR = 4.5, 95% CI, 1.5-13.1; P = 0.002) and a lower baseline CD4 count (RR = 0.997, 95% CI 0.995-0.999; P = 0.009 per each unit) remained statistically significant.
CKD was finally observed in six cases (2%, IR 1.49 episodes/100 patient-years, 95% CI, 1.21-1.76) associated with the presence of hypertension (67 versus 3%; P < 0.001), prior renal disease (50 versus 0%: P < 0.001), an eGFR <90 mL/min/ 1.73 m 2 (67 versus 26%; P = 0.045), a higher baseline sCr (1.18 ± 0.26 versus 0.88 ± 0.1 mg/dL; P = 0.038), a lower eGFR (75.8 ± 18.5 versus 105 ± 22 mL/min/1.73 m 2 ; P = 0.001) and a previous episode of AKI (67 versus 9%; P = 0.001). Therefore, renal disorder (AKI or CKD) was observed in 30 patients (11%), representing an IR of 7.46 events/100 person-years of follow-up (95% CI, 6.09-8.83).
AKI and tenofovir exposure
As mentioned, there were no differences in the baseline eGFR between patients initiating TDF or not, independently if they were receiving first line of HAART (108.2 versus 102.9 mL/min/1.73 m 2 , respectively), or were treatment experienced (104.4 mL/min/1.73 m 2 in both groups). After initiation, there was a marked decline in eGFR for patients receiving TDF (Figure 1 ). Thus, after 1 year of therapy, the mean decrease on TDF was −6.45 versus +0.98 mL/min/1.73 m 2 in patients not exposed to TDF (P < 0.01). This fact was observed in patients initiating HAART (−8. high incidence in TDF-exposed patients, there was no significant difference in the incidence of AKI (12 versus 7%, 22 cases and 6 cases, respectively, P = 0.15) according to TDF use ( Figure 2 ).
When analysing separately the different types of toxicity according to experience with therapy, AKI was present in 13% of first-line treated patients versus 9% of the treatment-experienced patients (P = 0.32). Analysing together HAART Values are shown as percentages or median (interquartile range), unless otherwise indicated. IDU, injection drug user; MSM, man having sex with man; TDF, tenofovir; ABC, abacavir; PI, protease inhibitor; DM, diabetes mellitus; HCV, hepatitis C virus; eGFR, estimated glomerular filtration rate; NSAID, non-steroidal anti-inflammatory drugs; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-II receptor blockers; SCr, serum creatinine.
O R I G I N A L A R T I C L E
A c u t e k i d n e y i n j u r y a n d H A A R T i n H I V p a t i e n t s experience and TDF use, patients on first line initiating TDF had a higher, but not significant, incidence of AKI (10 of 66; 15%), versus no cases in the not-TDF exposed. In contrast, in treatment-experienced patients, TDF-exposed patients had a diagnosis of AKI in 12 of 114 (11%) versus 5 of 82 (7%; P = 0.62).
Outcome after AKI Four patients with AKI progressed to CKD, in comparison with 2 of 241 patients who developed CKD without having previous diagnosis of AKI (14 versus 1%; P < 0.001). Nevertheless, it identified most of the patients finally diagnosed with CKD (67%). Three patients showed AKI at 3 months of follow-up, and at 6 months they fulfilled the criteria for CKD. The fourth patient presented AKI at 18 months of follow-up and fulfilled the CKD criteria at 24 months. These patients who progressed were older (mean age of 48.5 ± 10.7 years versus 39.9 ± 7.9; P = 0.068), had a lower baseline eGFR (82.1 ± 20.1 versus 122 ± 30.6 mL/min/1.73 m2; P = 0.019), a higher SCr (1.08 ± 0.27 versus 0.79 ± 0.15 mg/dL; P = 0.003) and a higher prevalence of hypertension (50 versus 4%; P = 0.045). The remaining 24 patients (86%) with AKI did not progress to CKD during a mean follow-up of 316 ± 232 days. Of them, 20 (73%) did not recover and still showed more than a 25% decrease in eGFR at the end of the follow-up [a median follow-up after AKI: 9 months (4.46-14.7)]. These patients did not change therapy during the follow-up, and persisted with an eGFR >70 mL/min/1.73 m 2 . Moreover, during this time of follow-up, three patients died, not related to renal or cardiovascular disease.
The mean eGFR decrease during the first year for patients initiating TDF or not.
The incidence of AKI and CKD according to previous therapy and first use of tenofovir.
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D I S C U S S I O N
Our study in this cohort of ambulatory HIV-infected patients, with a homogeneous clinical management at the same unit, shows a high incidence of AKI, but a low risk of progression to CKD after initiation of HAART in the current era, highlighting the importance of antiretroviral therapy as cause of AKI.
Also, this study offers important data about the extent and the importance of the definition used. We established AKI as a decrease in eGFR of at least 25%, considered 'risk' in the RIFLE definition [17] . The RIFLE criteria have been tested in clinical practice and seems to be at least coherent with regard to outcome of the patient with AKI [19, 20] . However, few studies have used these cut-off values before establishing renal toxicity in patients receiving HAART.
In this study, AKI was observed in 10% of patients, representing an incidence of 6.98 episodes/100 patient-years. In a similar study, including ambulatory HIV-positive patients followed between 2000 and 2002 (before the widespread use of TDF), the incidence of AKI was 5.9 cases per 100 patientyears. However, AKI was defined as a rise in SCr depending on the baseline creatinine, and causes not related to drugs were frequently observed [21] .
Although AKI is an 'acute' event, and therefore, as other acute events, usually recoverable, it has been associated with increased length of stay and increased in-hospital morbidity and mortality [22] . AKI in hospitalized naive HIV-1-infected patients is associated with a 6-fold higher risk of in-hospital mortality [23] , and it remains a strong predictor of mortality in the HAART era. In a recent cohort study, mortality was 31% among HIV-infected patients with AKI [24] . In a study of hospitalized HIV patients, AKI stage 1 was associated with death and ESRD, but not heart failure or other cardiovascular diseases [25] . However, as could be expected, prognosis in AKI varies with severity and aetiology, and in a short follow-up, we have not found an increased mortality rate in our ambulatory patients.
In our study, 14% of patients developing AKI progressed to CKD. In other studies, regarding hospitalized patients, between 13 and 37% of patients suffering AKI develop endstage renal disease after discharge [26] , highlighting the importance of an AKI diagnosis. The four patients developing CKD after a previous episode of AKI were older, had a higher prevalence of hypertension and a worse baseline renal function, highlighting the importance of classical factors in producing structural renal damage.
However, and despite the high incidence of AKI, only six patients (2%) developed CKD. This rate of 1.49 events/100 person-years for CKD is similar to that described previously. In the EuroSida study the IR ratio of developing CKD for cumulative exposure to tenofovir was 1.16 [27] . The DART trial examined 3316 ART-naive adults who were initiated on HAART including tenofovir (74%), concluding that severe kidney dysfunction (<30 mL/min/1.73 m 2 ) occurred in only 2.7% of patients on all regimens and contributed to death in a minority of patients [28] .
Moreover, most of our cases of AKI could be classified within the first stratum of the RIFLE criteria (risk), where the physician's awareness of the presence of risk for renal injury, at a moment when the situation is still reversible. In our study, 24 of 28 patients (86%) with a previous diagnosis of AKI did not progress without discontinuing antiretroviral therapy. Even 17% did not meet the criteria of AKI at the end of follow-up. However, these patients could remain at increased risk of CKD [9, 29] , a fact that highlights the need for careful monitoring and control of these patients, although the effect of changing therapy is not clear [30] .
In the multivariate analysis, a lower baseline CD4 count and the use of cotrimoxazole were statistically associated with renal toxicity. Advanced immunosuppression has already been described as a risk factor for renal disease [31] , but to our knowledge, no clinical study has highlighted the role of cotrimoxazole together with an increased risk of TDF renal toxicity, although previous studies have described the relationship between antiretroviral renal toxicity and use of cotrimoxazole [32] . This drug can produce tubular injury, crystalluria and acute interstitial nephritis [33] . Trimethoprim is also a known inhibitor of tubular secretion [34] that could affect the renal clearance of some antiretroviral drugs [35] , but it uses different cellular transporters than TDF and there are no data to suggest increased intracellular TDF levels and related toxicity. On the other hand, the inhibition of tubular secretion of creatinine by trimethoprim could lead to elevations in SCr that do not reflect true decrements in GFR [36] .
Of note, a higher eGFR was related to nephrotoxicity, a fact previously found in the literature [37] . Previous studies have found a relationship between higher plasma drug levels of TDF and renal toxicity, suggesting a role for higher concentrations of TDF in kidney [38] . Nevertheless, the eGFR by the MDRD equation was originally derived from patients with stable CKD with an average GFR of 40 mL/min/1.73 m 2 but has not been validated in patients with very high GFR, and higher GFR estimates are unlikely to be accurate or precise [39] . Moreover, this relationship was not statistically significant (P = 0.1) when the CKD-epi equation instead of MDRD was used.
Our study has several limitations. First, treatment-experienced patients could reflect a population of selected patients, since previous renal toxicity could influence the choice of ART. However, we did not find any difference regarding the renal function between naïve and treatment-experienced patients. Secondly, the most important limitation is the lack of randomization, since this could introduce bias in the risk of toxicity. But our study reflects the clinical setting, in which the risk factors for renal toxicity are part of a global decision about the best choice of antiretroviral regimen. Finally, AKI criteria were based on eGFR. It is widely accepted that GFR is the most useful overall index of kidney function in health and disease, and in clinical practice, an abrupt decline in GFR is assessed from an increase in SCr or oliguria [9] . The ambulatory management of patients does not permit a strict definition of AKI based on the time to renal function decline. Moreover, we have not measured markers of tubular dysfunction or other urine markers, and reported cases of TDF-associated nephrotoxicity suggest that it most typically manifests as proximal tubular injury with associated reduction in glomerular filtration [40] .
In conclusion, our study highlights the importance of using an established definition of renal toxicity and the clinical significance of AKI in patients receiving HAART, especially in terms of progression to CKD. Of note, the use of cotrimoxazole was independently associated with AKI. Tenofovir use was consistently associated with a higher decrease in eGFR and a higher incidence of AKI. Nevertheless, it seems prudent to limit exposure to this agent in patients with risk factors whenever possible and to weigh the risk of developing or worsening AKI against the risk associated with not using the drug.
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